Quinolines and aza-quinolines as CRTH

1. A compound of the formula (IA) or a pharmaceutically acceptable salt thereof,

wherein

J 1 is C(H) or N;

one of J a and J b is N, and the other is C(H);

R 6a and R 6b are independently:

a. H,

b. C 1 -C 10 alkyl,

c. -Q-R AH , wherein R AH is selected from the group consisting of:

and wherein R AH is unsubstituted or substituted with 1 moiety selected from the group consisting of Cl, —CN, —CH 3 , —CF 3 , and —OCF 3 ;

Q is selected from the group consisting of a

(i) bond;

(ii) C 1 -C 3 alkylene, wherein said alkylene is unsubstituted or substituted by one —CH 3 , —CF 3 , or —CH 2 CH 2 OH; and

d. -Q-R HC , wherein

Q is as set forth in c. above;

R HC is selected from the group consisting of:

and wherein R HC is unsubstituted or substituted with 1 to 2 R 12 moieties independently selected from the group consisting of fluoro and chloro, or wherein when two R 12 moieties are geminally substituted on the same carbon atom, the two geminally substituted R 12 moieties, together with the carbon atom on which they are attached form —C(O)—;

e. or R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is independently selected from the group consisting of:

wherein R 6H is unsubstituted or substituted by one R 9 moiety which is —Z—R CY wherein

Z is a bond; and

R CY is selected from the group consisting of:

and

wherein R CY is unsubstituted or substituted by 1 to 2 R 10 moieties, wherein each R 10 moiety is independently selected from the group consisting of fluoro and chloro; and

R 5 is absent or present, and if present, is halo.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of the formula (IA) has the formula (IB)

wherein one of J a and J b is N and the other is C(H);

a) R 6a is H and

R 6b is -Q-R AH , wherein R AH is phenyl,

wherein R AH is unsubstituted or substituted with moiety independently selected from the group consisting of fluoro, chloro, C 1 -C 3 alkyl, and —O—(C 1 -C 3 fluoroalkyl);

Q is methylene, wherein said methylene is unsubstituted or substituted by one C 1 -C 3 alkyl or C 1 -C 3 fluoroalkyl;

b) R 6a is H and

R 6b is -Q-R HC , wherein

Q is as set forth in a) above;

R HC is selected from the group consisting of:

and wherein R HC is unsubstituted or substituted with 1 chloro;

c) or R 6a and R 6b together with the N atom to which they are attached form

R 6H , wherein R 6H is

and

R 5 is absent or present, and if present, is fluoro.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein J 1 is C(H), J a is C(H) and J b is N.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein J 1 is C(H), J a is N and J b is C(H).

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein J 1 is N, J a is C(H) and J b is N.

6. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein J a is C(H) and J b is N.

7. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein J a is N and J b is C(H).

8. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(1) 2-phenyl-6-[[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]-3-quinolinepentanoic acid;

(1D 6-[[[(3-chlorophenyl)methyl]amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(1E) 6-[[[(4-methylphenyl)methyl]amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(1L) 2-phenyl-6-[(3(R)-phenyl-1-piperidinyl)carbonyl]-3-quinolinepentanoic acid;

(1T) 2-phenyl-6-[[(1(S)-phenylethyl)amino]carbonyl]-3-quinolinepentanoic acid;

(1AD) 6-[[[1(R)-(4-chlorophenyl)ethyl]amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(1AE) 6-[[[1(S)-(4-chlorophenyl)ethyl]amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(1AF) 6-[[[1(R)-(4-chlorophenyl)-2,2,2-trifluoroethyl]amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(1AG) 6-[[[1(S)-(4-chlorophenyl)-2,2,2-trifluoroethyl]amino]carbonyl]-3-phenyl-2-quinolinepentanoic acid;

(1M) 6-[[(2,3-dihydro-1H-inden-1(R)-yl)amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(2) 2-phenyl-6-[[(phenylmethyl)amino]carbonyl]-3-quinolinepentanoic acid;

(2C) 6-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-phenyl-3-quinolinepentanoic acid;

(3E) 3-phenyl-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinolinepentanoic acid;

(4) 5-(7-(3-chlorobenzylcarbamoyl)-3-phenylquinolin-2-yl)pentanoic acid;

(4E) (R)-5-(7-(1-(4-fluorophenyl)ethylcarbamoyl)-3-phenylquinolin-2-yl)pentanoic acid;

(5G) 2-(4-fluorophenyl)-6-[[(1,2,3,4-tetrahydro-1(R)-naphthalenyl)amino]carbonyl]-3-quinolinepentanoic acid;

(5o) 6-[[(5-chloro-2,3-dihydro-1H-inden-1(R)-yl)amino]carbonyl]-2-(4-fluorophenyl)-3-quinolinepentanoic acid; and

(6G) 6-[[(6-chloro-1,2,3,4-tetrahydro-1(R)-naphthalenyl)amino]carbonyl]-2-(4-fluorophenyl)-1,8-naphthyridine-3-pentanoic acid.

9. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(1AH) (R)-5-(6-((1-(4-fluorophenyl)ethyl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1Ai) 5-(2-phenyl-6-(4-phenylpiperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(1AJ) 5-(6-(3-(3-fluorophenyl)azetidine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AK) 5-(6-((4-fluorobenzyl)(methyl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AL) (S)-5-(6-(chroman-4-ylcarbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AM) (R)-5-(6-(3-(4-fluorophenyl)pyrrolidine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AN) (S)-5-(6-(3-(4-fluorophenyl)pyrrolidine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1Ao) (R)-5-(6-((2,3-dihydrobenzofuran-3-yl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AP) 5-(6-((2,2-dimethylchroman-4-yl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AQ) 5-(6-((4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AR) 5-(6-(3-cyano-3-phenylpyrrolidine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AS) 5-(6-((2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AT) 5-(6-((2-(4-fluorophenyl)propan-2-yl)carbamoyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AU) 5-(6-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AV) 5-(2-phenyl-6-(3H-spiro[isobenzofuran-1,4′-piperidin]-1′-ylcarbonyl)quinolin-3-yl)pentanoic acid;

(1AW) 5-(2-phenyl-6-(4-(pyridin-2-yl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(1AX) 5-(6-(4-(3-cyanopyridin-2-yl)piperazine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AY) 5-(6-(4-(3,5-dichloropyridin-4-yl)piperazine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1AZ) 5-(6-(4-(2-cyanophenyl)piperazine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1BA) 5-(6-(4-(2-chlorophenyl)piperazine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1BB) 5-(2-phenyl-6-(4-(o-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(1BC) 5-(2-phenyl-6-(4-(m-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(1BD) 5-(6-(4-(4-methoxyphenyl)piperazine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(1BE) 5-(6-(4-(3-methylpyridin-4-yl)piperazine-1-carbonyl)-2-phenylquinolin-3-yl)pentanoic acid;

(5AA) 5-(6-(benzhydrylcarbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AB) (R)-5-(2-(4-fluorophenyl)-6-((2-phenylpropyl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5AC) (S)-5-(2-(4-fluorophenyl)-6-((2-phenylpropyl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5AD) (R)-5-(6-(chroman-4-ylcarbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AE) (R)-5-(6-((6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AF) 5-(2-(4-fluorophenyl)-6-(4-phenylpiperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AG) 5-(2-(4-fluorophenyl)-6-(3-(3-fluorophenyl)azetidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AH) (S)-5-(2-(4-fluorophenyl)-6-(3-phenylpyrrolidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5Ai) 5-(6-((4-fluorobenzyl)(methyl)carbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AJ) 5-(6-((2,2-dimethylchroman-4-yl)carbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AK) 5-(6-((4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AL) 5-(2-(4-fluorophenyl)-6-((2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5AM) 5-(2-(4-fluorophenyl)-6-(3-phenylazetidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AN) 5-(6-(benzylcarbamoyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5Ao) 5-(6-(4-(2-cyanophenyl)piperazine-1-carbonyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AP) 5-(2-(4-fluorophenyl)-6-(4-(2-methoxyphenyl)piperidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AQ) 5-(2-(4-fluorophenyl)-6-(3H-spiro[isobenzofuran-1,4′-piperidin]-1′-ylcarbonyl)quinolin-3-yl)pentanoic acid;

(5AR) 5-(2-(4-fluorophenyl)-6-(4-(2-(trifluoromethyl)phenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AS) 5-(6-(4-(2-chlorophenyl)piperazine-1-carbonyl)-2-(4-fluorophenyl)quinolin-3-yl)pentanoic acid;

(5AT) 5-(2-(4-fluorophenyl)-6-(4-(o-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AU) 5-(2-(4-fluorophenyl)-6-(4-(m-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AV) 5-(2-(4-fluorophenyl)-6-(4-(4-methoxyphenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AW) 5-(2-(4-fluorophenyl)-6-(4-(p-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AX) 5-(2-(4-fluorophenyl)-6-(4-(4-fluorophenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5AY) (R)-5-(2-(4-chlorophenyl)-6-((6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5AZ) (R)-5-(2-(4-chlorophenyl)-6-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5BA) (R)-5-(2-(4-chlorophenyl)-6-(chroman-4-ylcarbamoyl)quinolin-3-yl)pentanoic acid;

(5BB) (S)-5-(2-(4-chlorophenyl)-6-((2,3-dihydrobenzofuran-3-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5BC) (R)-5-(2-(4-chlorophenyl)-6-((1-(4-fluorophenyl)ethyl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5BD) 5-(2-(4-chlorophenyl)-6-(4-phenylpiperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BE) 5-(2-(4-chlorophenyl)-6-(3-(3-fluorophenyl)azetidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BF) (S)-5-(2-(4-chlorophenyl)-6-(3-phenylpyrrolidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BG) 5-(2-(4-chlorophenyl)-6-((4-fluorobenzyl)(methyl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5BH) 5-(2-(4-chlorophenyl)-6-((2,2-dimethylchroman-4-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5Bi) 5-(2-(4-chlorophenyl)-6-((4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5BJ) 5-(2-(4-chlorophenyl)-6-((2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)carbamoyl)quinolin-3-yl)pentanoic acid;

(5BK) 5-(2-(4-chlorophenyl)-6-(3-phenylazetidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BL) 5-(6-(benzylcarbamoyl)-2-(4-chlorophenyl)quinolin-3-yl)pentanoic acid;

(5BM) 5-(2-(4-chlorophenyl)-6-(4-(2-cyanophenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BN) 5-(2-(4-chlorophenyl)-6-(4-(2-methoxyphenyl)piperidine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5Bo) 5-(2-(4-chlorophenyl)-6-(3H-spiro[isobenzofuran-1,4′-piperidin]-1′-ylcarbonyl)quinolin-3-yl)pentanoic acid;

(5BP) 5-(2-(4-chlorophenyl)-6-(4-(2-chlorophenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BQ) 5-(2-(4-chlorophenyl)-6-(4-(o-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BR) 5-(2-(4-chlorophenyl)-6-(4-(m-tolyppiperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BS) 5-(2-(4-chlorophenyl)-6-(4-(4-methoxyphenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid;

(5BT) 5-(2-(4-chlorophenyl)-6-(4-(p-tolyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid; and

(5BU) 5-(2-(4-chlorophenyl)-6-(4-(4-fluorophenyl)piperazine-1-carbonyl)quinolin-3-yl)pentanoic acid.

10. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A method for treating a disease or condition which is asthma, congestion, allergic rhinitis or COPD comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the disease or condition is asthma.